Home / Health / New TB Vaccine Promises Hope Against Deadly Disease
New TB Vaccine Promises Hope Against Deadly Disease
25 Nov
Summary
- A new HSP Subunit Vaccine is nearing commercial availability.
- Existing vaccines are largely ineffective for adult TB prevention.
- IIT Bhubaneswar and ILS Bhubaneswar developed the novel vaccine.
A new generation HSP Subunit Vaccine, designed to combat Mycobacterium tuberculosis, is approaching commercial availability. Developed through collaborative research between the Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar, this vaccine addresses the critical gap in preventing pulmonary tuberculosis in adolescents and adults.
The existing Bacillus Calmette Guérin (BCG) vaccine, over a century old, provides only limited protection to infants and is largely ineffective in older age groups. Tuberculosis remains a significant global health threat, with the WHO reporting 1.23 million deaths in 2024 alone, underscoring the urgent need for improved prevention strategies.
TechInvention Lifecare Limited has entered into a license agreement for the technology transfer and commercialization of this novel vaccine. This partnership aims to efficiently translate the indigenous vaccine technology from research to product development and eventual market availability, marking a significant step forward in India's efforts to control the TB epidemic.
